308 related articles for article (PubMed ID: 33382205)
41. Predictors of efficacy of anamorelin in patients with non‑small cell lung cancer and cachexia: A retrospective study.
Ishioka Y; Tanaka H; Makiguchi T; Fujishima S; Nunomura Y; Sakamoto H; Shiratori T; Taima K; Tasaka S
Oncol Lett; 2024 Jan; 27(1):22. PubMed ID: 38058465
[TBL] [Abstract][Full Text] [Related]
42. Mechanisms of anorexia-cachexia syndrome and rational for treatment with selective ghrelin receptor agonist.
Esposito A; Criscitiello C; Gelao L; Pravettoni G; Locatelli M; Minchella I; Di Leo M; Liuzzi R; Milani A; Massaro M; Curigliano G
Cancer Treat Rev; 2015 Nov; 41(9):793-7. PubMed ID: 26386985
[TBL] [Abstract][Full Text] [Related]
43. Systemic inflammation adversely affects response to anamorelin in patients with pancreatic cancer.
Tsunematsu M; Uwagawa T; Onda S; Shirai Y; Okui N; Matsumoto M; Furukawa K; Haruki K; Ishizaki S; Ikegami T
Support Care Cancer; 2023 Nov; 31(12):732. PubMed ID: 38055066
[TBL] [Abstract][Full Text] [Related]
44. The efficacy and safety of anamorelin among patients with diabetes.
Ando K; Naito T; Hamauchi S; Miura K; Nishibori Y; Tonsho A; Matsuda S; Morita M; Sekikawa M; Doshita K; Kodama H; Yabe M; Morikawa N; Iida Y; Mamesaya N; Kobayashi H; Ryo K; Wakuda K; Ono A; Kenmotsu H; Murakami H; Yamazaki K; Takahashi T
Int J Clin Oncol; 2024 May; ():. PubMed ID: 38722487
[TBL] [Abstract][Full Text] [Related]
45. Effect of Anamorelin, a Ghrelin Receptor Agonist, on Muscle and Bone in Adults With Osteosarcopenia.
Dawson-Hughes B; Barger K; Reitshamer E; Fielding RA; Evans W; Ceglia L
J Clin Endocrinol Metab; 2024 Feb; 109(3):e945-e955. PubMed ID: 38057159
[TBL] [Abstract][Full Text] [Related]
46. Palliative care: Anamorelin provides benefit to patients with cachexia.
Sidaway P
Nat Rev Clin Oncol; 2018 Feb; 15(2):68. PubMed ID: 29255237
[No Abstract] [Full Text] [Related]
47. [Future Prospects of Cancer Cachexia].
Morita-Tanaka S; Takayama K
Gan To Kagaku Ryoho; 2022 Jul; 49(7):719-722. PubMed ID: 35851337
[TBL] [Abstract][Full Text] [Related]
48. Oncology Update: Anamorelin.
Prommer E
Palliat Care; 2017; 10():1178224217726336. PubMed ID: 28855797
[TBL] [Abstract][Full Text] [Related]
49. The landscape of cancer cachexia in advanced non-small cell lung cancer: a narrative review.
Morita-Tanaka S; Yamada T; Takayama K
Transl Lung Cancer Res; 2023 Jan; 12(1):168-180. PubMed ID: 36762058
[TBL] [Abstract][Full Text] [Related]
50. [Overview of Cancer-Associated Cachexia].
Takayama K
Gan To Kagaku Ryoho; 2019 Dec; 46(12):1814-1817. PubMed ID: 31879394
[TBL] [Abstract][Full Text] [Related]
51. Appetite and food intake results from phase I studies of anamorelin.
Blum RA; Mair S; Duus EM
J Cachexia Sarcopenia Muscle; 2019 Oct; 10(5):1027-1035. PubMed ID: 31074178
[TBL] [Abstract][Full Text] [Related]
52. What is next after anamorelin?
Garcia JM
Curr Opin Support Palliat Care; 2017 Dec; 11(4):266-271. PubMed ID: 28957883
[TBL] [Abstract][Full Text] [Related]
53. Anamorelin for the Treatment of Cancer Anorexia-Cachexia Syndrome.
Dev R; Amano K; Naito T; Del Fabbro E
Curr Oncol Rep; 2024 May; ():. PubMed ID: 38771469
[TBL] [Abstract][Full Text] [Related]
54. A randomized phase II study of nutritional and exercise treatment for elderly patients with advanced non-small cell lung or pancreatic cancer: the NEXTAC-TWO study protocol.
Miura S; Naito T; Mitsunaga S; Omae K; Mori K; Inano T; Yamaguchi T; Tatematsu N; Okayama T; Morikawa A; Mouri T; Tanaka H; Kimura M; Imai H; Mizukami T; Imoto A; Kondoh C; Shiotsu S; Okuyama H; Ueno M; Takahashi T; Tsuji T; Aragane H; Inui A; Higashiguchi T; Takayama K
BMC Cancer; 2019 May; 19(1):528. PubMed ID: 31151425
[TBL] [Abstract][Full Text] [Related]
55. A case of squamous cell lung cancer treated with anamorelin in combination with a multidisciplinary collaborative approach for treating cancer cachexia.
Oshima Y; Matsuura H; Sakurai Y; Hirai K; Tani E; Yoshimoto N; Minami K; Yamasaki F; Nishime M; Hirashima T
Respir Med Case Rep; 2022; 36():101609. PubMed ID: 35242522
[TBL] [Abstract][Full Text] [Related]
56. Quality of life and survival survey of cancer cachexia in advanced non-small cell lung cancer patients-Japan nutrition and QOL survey in patients with advanced non-small cell lung cancer study.
Takayama K; Atagi S; Imamura F; Tanaka H; Minato K; Harada T; Katakami N; Yokoyama T; Yoshimori K; Takiguchi Y; Hataji O; Takeda Y; Aoe K; Kim YH; Yokota S; Tabeta H; Tomii K; Ohashi Y; Eguchi K; Watanabe K
Support Care Cancer; 2016 Aug; 24(8):3473-80. PubMed ID: 27003901
[TBL] [Abstract][Full Text] [Related]
57. Cancer cachexia, sarcopenia and biochemical markers in patients with advanced non-small cell lung cancer-chemotherapy toxicity and prognostic value.
Srdic D; Plestina S; Sverko-Peternac A; Nikolac N; Simundic AM; Samarzija M
Support Care Cancer; 2016 Nov; 24(11):4495-502. PubMed ID: 27236439
[TBL] [Abstract][Full Text] [Related]
58. Anamorelin Induced Acute Hyperglycemia in a Patient with Advanced Pancreatic Cancer and Diabetes: A Case Report.
Yamamoto J; Onodera H; Kaminaga Y; Kayaba Y; Usui M
Tohoku J Exp Med; 2024 May; 262(4):263-268. PubMed ID: 38325830
[TBL] [Abstract][Full Text] [Related]
59. [Development of Therapy for Cancer Cachexia in Pancreatic Cancer].
Mitsunaga S
Gan To Kagaku Ryoho; 2022 Jul; 49(7):728-731. PubMed ID: 35851339
[TBL] [Abstract][Full Text] [Related]
60. Are measures and related symptoms of cachexia recorded as outcomes in gastrointestinal cancer chemotherapy clinical trials?
Valaire R; Garden F; Razmovski-Naumovski V
J Cachexia Sarcopenia Muscle; 2024 Jun; 15(3):1146-1156. PubMed ID: 38533530
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
